anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: GLUTAMIC ACID
Trial phase: Phase 3
ATC code: A09AB01
SMILES: NC(CCC(=O)O)C(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 148
Group description: Intravenous infusion of 0.125M L-glutamic acid solution at a rate of 1.65 ml/kg BW and hour commencing at or up to 20 minutes before the release of aortic cross-clamp. The infusion is continued for two hours after declamping the aorta after which an additional 50 ml is given at a halved infusion rate.

glutamate infusion: Intravenous infusion of 0.125M L-glutamic acid solution at a rate of 1.65 ml/kg BW and hour commencing at or up to 20 minutes before the release of aortic cross-clamp. The infusion is continued for two hours after declamping the aorta after which an additional 50 ml is given at a halved infusion rate.
Eligibility criteria:
Inclusion Criteria:

Patients accepted for coronary artery bypass surgery of at least two vessel disease or left main stenosis with or without concomitant procedure considered to be at moderate to high surgical risk preoperatively with regard to postoperative heart failure due to:

• EuroSCORE II ≥ 3.0 with at least one of the following cardiac or procedure related risk factors:

LVEF ≤ 0.50
CCS class IV
Recent Myocardial Infarct (≤ 90 days)
Emergency / Urgent procedure (as defined in EuroSCORE II)
CABG with aortic or mitral valve procedure

OR

• LVEF ≤ 0.30 regardless of EuroSCORE II

Exclusion Criteria:

age > 85 years
ambiguous food allergies that trigger shortness of breath, headache or flushing
previous cardiac surgery
patients who are in such bad condition that they cannot be asked to participate
patients who because of linguistic or other reasons are unable to provide informed consent
severe renal failure with preoperative dialysis or calculated GFR <30 mL / min
patients requiring mechanical circulatory support (intra-aortic balloon pump) due to circulatory failure before they are enrolled in the study
surgery without heart-lung machine (off-pump)
concomitant Maze-procedure
surgery of ascending aorta
surgery of both aortic and mitral valve
Intervention: SODIUM CHLORIDE
Trial phase: Phase 3
ATC code: A12CA01 | B05CB01 | B05XA03 | S01XA03
SMILES: [Cl-].[Na+]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 155
Group description: Intravenous infusion of saline at a rate of 1.65 ml/kg BW and hour commencing at or up to 20 minutes before the release of aortic cross-clamp. The infusion is continued for two hours after declamping the aorta after which an additional 50 ml is given at a halved infusion rate.

saline infusion: Intravenous infusion of saline at a rate of 1.65 ml/kg BW and hour commencing at or up to 20 minutes before the release of aortic cross-clamp. The infusion is continued for two hours after declamping the aorta after which an additional 50 ml is given at a halved infusion rate.
Eligibility criteria:
Inclusion Criteria:

Patients accepted for coronary artery bypass surgery of at least two vessel disease or left main stenosis with or without concomitant procedure considered to be at moderate to high surgical risk preoperatively with regard to postoperative heart failure due to:

• EuroSCORE II ≥ 3.0 with at least one of the following cardiac or procedure related risk factors:

LVEF ≤ 0.50
CCS class IV
Recent Myocardial Infarct (≤ 90 days)
Emergency / Urgent procedure (as defined in EuroSCORE II)
CABG with aortic or mitral valve procedure

OR

• LVEF ≤ 0.30 regardless of EuroSCORE II

Exclusion Criteria:

age > 85 years
ambiguous food allergies that trigger shortness of breath, headache or flushing
previous cardiac surgery
patients who are in such bad condition that they cannot be asked to participate
patients who because of linguistic or other reasons are unable to provide informed consent
severe renal failure with preoperative dialysis or calculated GFR <30 mL / min
patients requiring mechanical circulatory support (intra-aortic balloon pump) due to circulatory failure before they are enrolled in the study
surgery without heart-lung machine (off-pump)
concomitant Maze-procedure
surgery of ascending aorta
surgery of both aortic and mitral valve
Intervention: Oxalacetic acid
Trial phase: Phase 1
SMILES: O=C(O)CC(=O)C(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 15
Group description: Participants take 2 grams of OAA per day for period of 4 weeks

Oxaloacetate (OAA): Pills to be taken orally in 500mg or 1000mg doses two times per day depending on the part of the study
Eligibility criteria:
Inclusion Criteria:

Have a diagnosis of probable Alzheimer's disease (AD) per McKhann et al. criteria [9];
Have a clinical dementia rating (CDR) score of 0.5 or 1 at time of their last University of Kansas Alzheimer's Disease Center (KU ADC) assessment;
Have a Mini Mental Status Exam (MMSE) score of 15-28 at the TOAD screening visit;
Have a reliable and competent study partner who is willing to accompany the participant to all study visits, monitor compliance of study medication administration, and observe/report any changes in the participant's health throughout the study duration;
Are on stable doses of concurrent medications for at least 4 weeks prior to the TOAD screening visit; and
Speaks English as his/her primary language.
If female of child-bearing potential, must have a negative urine pregnancy test at TOAD screening visit (and must agree to use of contraception throughout the trial)

Exclusion Criteria:

Dementia due to causes other than AD;

Potentially confounding, serious, or unstable medical conditions such as:

insulin-dependent diabetes mellitus
cancer within the past 3 years (except basal cell, squamous cell, or localized prostate cancer)
a recent cardiac event (i.e. heart attack, angioplasty, etc. within the 6 months prior to screening visit)
other conditions that pose a potential safety risk or confounding factor in the investigator's opinion;
Any abnormal physical examination assessment or vital sign assessment at TOAD screening visit that is deemed to be clinically significant by the principal investigator;
Any abnormal clinical laboratory test result at TOAD screening visit that is deemed to be clinically significant by the principal investigator.
Any contraindication for undergoing magnetic resonance spectroscopy (MRS), such as the presence of metal implants, a cardiac pacemaker that is not compatible with MRS, or severe claustrophobia
Intervention: Bumetanide
Trial phase: Not Applicable
ATC code: C03CA02 | C03CB02 | C03EB02 | G01AE10
SMILES: CCCCNc1cc(C(=O)O)cc(S(N)(=O)=O)c1Oc1ccccc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 11
Group description: Isothermic dialysate (37°C) and bumetanide (diuretic)

Bumetanide: Diuretic
Eligibility criteria:
Inclusion Criteria:

Primary speaking language is English.
Patient is HD naïve (Patient may still enroll as long as no more than 12 weeks of in-center HD have been performed prior to randomization)
HD takes place at one of the participating Dialysis Clinic Inc. (DCI) sites during the data collection period.
Daily urine output is over 500ml.
Patients must be willing and able to sign the consent form.

Exclusion Criteria:

RRF <5 mL/min/1.73 m2 as determined by iohexol GFR measurement.
Allergy or contraindication to iohexol and/or bumetanide.
Has been undergoing dialysis for more than 12 weeks.
Expectation that native kidneys will recover.
History of poor adherence to treatment.
Unable to verbally communicate in English.
Requires more than 3 HD treatments per week due to medical co-morbidity (such as, but not limited to: severe volume overload requiring frequent HD e.g. in systemic oxalosis, or requiring total parenteral nutrition).
Scheduled for living donor kidney transplant in the next 6 months.
Intention to change to peritoneal dialysis, or home HD in the next 6 months.
Plan to relocate to another center within the next 7-8 months.
Expected geographic unavailability at a participating HD unit for >2 consecutive weeks or >4 weeks total during the next 6 months (excluding unavailability due to hospitalizations)
Post kidney transplantation
Currently in an acute or chronic care hospital
Life expectancy <6 months or intention to withdraw dialysis therapy within 6 months.
Current pregnancy
Actively planning to become pregnant in the next 8 months
Nursing mothers
Current use of investigational drugs
Participation in another non-observational clinical trial that contradicts or interferes with the therapies or measured outcomes in this trial
Unable or unwilling to follow the study protocol for any reason (including mental incompetence)
Unable or unwilling to provide informed consent or sign IRB-approved consent form.

The following special populations will not be included in this study:

Patients who are too infirm or lack the capacity to meaningfully participate in medical decisions and to sign the informed consent.
Children and adolescents constitute <2% of the dialysis population, and our preliminary survey of the study sites found no children and adolescents were active patients. In any case, the renal and other physical factors of children and adolescents with ESRD are not directly comparable to those of adults.
Prisoners.
Intervention: Sulfamethoxazole
Trial phase: Not Applicable
ATC code: G01AE10 | J01EC01 | J01EE01 | J04AM08
SMILES: Cc1cc(NS(=O)(=O)c2ccc(N)cc2)no1
Sex: Male
Age groups: Child
Healthy volunteers: No
Participants at risk: 67
Group description: Patients randomized to this arm will receive prophylactic oral antibiotics following the surgery and catheter placement (Septra, 3 mg/kg/dose once daily), and will continue the medication for until the day before catheter removal 4-8 days post-operation.
Eligibility criteria:
Inclusion Criteria:

all children between ages 6 months to 2 years under going distal or mid shaft hypospadias repair
children of parents who give informed consent
English speaking
participant must be available for follow-up 3 and 12 months post-surgery

Exclusion Criteria:

all proximal hypospadias and redo hypospadias repairs
children who are allergic to sulfa medications
patients who have UTI at time of surgery (proven by culture)
Intervention: Ademetionine
Trial phase: Phase 3
ATC code: A16AA02
SMILES: C[S+](CC[C@H](N)C(=O)[O-])C[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O
Sex: All
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 61
Group description: DSXS Active treatment

DSXS: Active treatment
Eligibility criteria:
Inclusion Criteria:

- male and non-pregnant females, age 6 months or older, with a confirmed diagnosis of moderate to severe atopic dermatitis (AD)

Exclusion Criteria:

- Lacks stable diagnosis of atopic dermatitis or has been diagnosed with mild atopic dermatitis.
Intervention: Kenalog
Trial phase: Phase 3
SMILES: CC1(C)OC2CC3C4CCC5=CC(=O)C=CC5(C)C4(F)C(O)CC3(C)C2(C(=O)CO)O1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 96
Group description: Suprachoroidal injection of 40 mg/mL (4 mg in 100 µL) of CLS-TA

4mg CLS-TA Suprachoriodal Injection: CLS-TA, 40 mg/mL (4 mg in 100 µL), administered as a single injection at 2 timepoints
Eligibility criteria:
Inclusion Criteria:

Diagnosis of non-infectious uveitis (pan, anterior, intermediate and posterior)
Diagnosis of macular edema associated with non-infectious uveitis (retinal thickness ≥ 300 microns)
Visual Acuity score of ≥ 5 letters read (20/800 Snellen equivalent) and ≤ 70 letters read (20/40 Snellen equivalent), in the study eye

Exclusion Criteria:

Any active ocular disease or infection in the study eye other than uveitis
Intraocular pressure > 22 mmHg or uncontrolled glaucoma in the study eye; subjects are not excluded if IOP ≤ 22 mmHg with no more than 2 IOP lowering medications.
Any uncontrolled systemic disease that, in the opinion of the Investigator, would preclude participation in the study
Any topical ocular corticosteroid in the 10 days prior to baseline; intraocular or periocular corticosteroid injections in the 2 months prior to baseline; an OZURDEX implant in the 6 months prior to baseline; RETISERT or ILUVIEN implant in the 3 years prior to baseline.
Intervention: OXYTOCIN
Trial phase: Phase 4
ATC code: H01BB02
SMILES: CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CSSC[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O
Sex: All
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 83
Group description: Participants received a single 40 IU dose of Pitocin (oxytocin, USP; concentration = 10 IU/1 mL; PAR Pharmaceuticals, NY, USA) during the first or second experimental session. The second experimental session was completed at least 72 hours after the first. All nasal spray solutions were transferred into two, 2 ml intranasal atomizers and administered in four sprays to each nostril over the course of 10 minutes.
Eligibility criteria:
Inclusion Criteria:

Ages 18-40
Smoke >= 10 cig/day for the past year
English fluency

Exclusion Criteria:

Current DSM-5 substance use disorder, excluding nicotine dependence (to minimize alcohol or drug withdrawal symptoms during the study sessions)
Any medical condition that would increase risk for study participation (such as sinus infection or other condition blocking access to the olfactory epithelium)
Women who are pregnant or nursing
Current use of psychiatric medication
Breath Carbon Monoxide (CO) levels < 10ppm measured during study intake (to exclude individuals who overreport smoking in order to participate in the study)
Planning to quit or reduce smoking in the next 30 days
Current regular use of other nicotine products
Intervention: Propranolol
Trial phase: Phase 2
ATC code: C07AA05 | C07BA05 | C07FX01
SMILES: CC(C)NCC(O)COc1cccc2ccccc12
Sex: All
Age groups: Child | Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 1
Group description: Patients will be given propranolol in escalating doses

Propranolol: escalating doses of propranolol from 1mg/kg/day to 2mg/kg/day to 3mg/kg/day
Eligibility criteria:
Inclusion Criteria:

Primary lymphedema
Measurable disease
Adequate functional status: Karnofsky >50% (>age 16), Lanky >50 (<age 16),
No prior therapy within 4 weeks of enrollment
Adequate bone marrow, renal function, cardiac, and pulmonary function, negative pregnancy test (for women).

Exclusion Criteria:

Secondary lymphedema
Patients already receiving other investigational drugs
Patients with known contraindications to receiving propranolol
Other medical comorbidities including but not limited to: pheochromocytoma, bradycardia, bronchospasm/reactive airway disease, decompensated heart failure, heart block, ongoing active infections.
Intervention: Propranolol
Trial phase: Phase 2
ATC code: C07AA05 | C07BA05 | C07FX01
SMILES: CC(C)NCC(O)COc1cccc2ccccc12
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 2
Group description: all subjects will receive the experimental drug

propanolol: Participants will take 1.5 mg/kg/day propranolol, twice daily for 3 weeks until surgical resection of the breast tumor is performed
Eligibility criteria:
Inclusion Criteria:

Ages 18- 65
diagnosis of stage I-III breast cancer , confirmed by a core biopsy
Planning to undergo definitive surgery including mastectomy or breast conserving surgery
Systolic blood pressure must be >100 mmHg but no more than 140 mmHg and/or diastolic > 60 mmHg and no more than 95 mmHg.
normal baseline EKG

Exclusion criteria:

Pregnancy; potential subjects of female bearing age will have to complete a pregnancy test during screening to ensure that they are not pregnant. Potential patients who are post-menopausal must have confirmed one year without menstrual cycle.
Free of major medical illnesses including:
Uncontrolled Diabetes (HbA1c of ≤ 8 if previously tested)
Uncontrolled hypertension: BP >systolic 140/ diastolic > 95
Cardiac diseases (history of cardiac valve disease, coronary artery disease, congestive heart failure, A-V block, peripheral vascular disease, any cardiac arrhythmia/bradycardia) with the exception of the diagnosed cancer.
Histories of asthma, bronchospastic disease, or obstructive pulmonary disease
Previously diagnosed thyrotoxicosis
Severe allergic reactions to medications which are included in the beta blocker family
Previously or currently treated with a beta adrenergic receptor antagonist
Patients with locally advanced or inflammatory breast cancer not amenable to surgical resection

Patients taking any of the following medications will be excluded:

Drugs that are categorized as digitalis glycosides, beta-blockers and calcium channel blockers, ACE inhibitors and alpha blockers
Amiodarone
Cimetidine
Ciprofloxacin
Delavudin
Dobutamine
Ethanol
Fluconazole
Fluoxetine
Fluvoxamine
Haloperidol
Imipramine
Isoniazid
Isoproterenol
Luvoxamine
Paroxetine
Phenytoin
Phenobarbital.
Propafenone.
Quinidine
Reserpine
Rifampin
Ritonavir
Rizatriptan.
Tenioposide
Theophylline
Thyroxine
Tolbutamide.
Warfarin
Zileuton
Zolmitriptan
Intervention: Nintedanib
Trial phase: Phase 3
ATC code: L01EX09
SMILES: COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 288
Group description: Patients were administered orally 150 milligram (mg) soft gelatin capsules, twice daily with a possibility to interrupt treatment or to reduce to 100mg to manage adverse events.
Eligibility criteria:
Inclusion criteria:

Age >= 18 years
2013 American College of Rheumatology (ACR) / EULAR classification criteria for SSc fulfilled
SSc disease onset (defined by first non-Raynaud symptom) within 7 years
SSc related Interstitial Lung Disease confirmed by High Resolution Computer Tomography (HRCT); Extent of fibrotic disease in the lung >= 10%
FVC >= 40% of predicted normal
Carbon Monoxide Diffusion Capacity (DLCO) 30% to 89% of predicted normal

Exclusion criteria:

Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) >1.5 x ULN
Bilirubin >1.5 x ULN
Creatinine clearance <30 mL/min
Airway obstruction (pre-bronchodilator Forced Expiratory Volume in 1 second (FEV1)/FVC <0.7)
Other clinically significant pulmonary abnormalities
Significant Pulmonary Hypertension (PH)
Cardiovascular diseases
More than 3 digital fingertip ulcers or a history of severe digital necrosis requiring hospitalization or severe other ulcers
Bleeding risk (such as predisposition to bleeding, fibrinolysis, full-dose anticoagulation, high dose antiplatelet therapy, history of hemorrhagic central nervous system (CNS) event within last year
international normalised ratio (INR) >2, prolongation of prothrombin time (PT) and partial thromboplastin time (PTT) by >1.5 x ULN)
History of thrombotic event within last year
Clinical signs of malabsorption or needing parenteral nutrition
Previous treatment with nintedanib or pirfenidone
Treatment with prednisone >10 mg/day, azathioprine, hydroxychloroquine, colchicine, D-penicillamine, sulfasalazine, cyclophosphamide, rituximab, tocilizumab, abatacept, leflunomide, tacrolimus, newer anti-arthritic treatments like tofacitinib and cyclosporine A, potassium para-aminobenzoate
Unstable background therapy with either mycophenolate mofetil or methotrexate
Previous or planned hematopoietic stem cell transplantation
Patients with underlying chronic liver disease (Child Pugh A, B, C hepatic impairment)
Intervention: Ruxolitinib
Trial phase: Phase 3
ATC code: D11AH09 | L01EJ01 | L01XE18
SMILES: N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 24
Group description: Two tablets of ruxolitinib 5 mg were administered orally twice per day
Eligibility criteria:
Inclusion Criteria:

Confirmed diagnosis of MF with bone marrow fibrosis of at least Grade 1; irrespective of JAK2 mutational status
Patients with at least one mutation in one of the five HMR genes (ASXL1, EZH2, SRSF2 and IDH1/2)
Patients with non-palpable spleen or spleen palpable ≤ 5 cm from the left costal margin to the point of greatest splenic protrusion
Patients with MF-7 score of ≤ 15, with each individual symptom score of ≤ 3

Exclusion Criteria:

Patients with prior treatment with ruxolitinib or other JAK inhibitors.
Intervention: Acetylcarnitine
Trial phase: Phase 2
ATC code: N06BX12
SMILES: CC(=O)OC(CC(=O)[O-])C[N+](C)(C)C
Sex: All
Age groups: Child | Adult
Healthy volunteers: No
Participants at risk: 8
Group description: The first 15 subjects participating in this study will receive Acetyl-L-Carnitine and pharmacokinetic testing will be done.

Acetylcarnitine: Acetylcarnitine is taken 2 times a day for days 1 through 21.
Eligibility criteria:
Inclusion Criteria:

Subjects must meet the following inclusion criteria.

The subject must have a confirmed diagnosis of acute lymphoblastic leukemia within 1 week of starting therapy
Currently being treated on a standard ALL induction regimen
Subjects must be greater than or equal to 5 and less than 18 years old
Signed informed consent

Exclusion Criteria:

Subjects will be excluded for the following:

Preexisting neurologic disease, including grade II, III, or IV neurological status by NCI Common Toxicity Criteria v3.0 on clinical exam
History of hypersensitivity to vincristine
History of hypersensitivity to Acetyl-L-carnitine
Previous use of Acetyl-L-carnitine
Concurrent anti-convulsant use
Concurrent Gabapentin use
Concurrent Glutamine use
Liver Function: Total bilirubin greater than 1.3 mg/dL and serum glutamic-pyruvic transaminase (SGPT) (ALT) greater than 5 x upper limit of normal for age and serum albumin less than 2 g/dL
Patients who are pregnant
Intervention: Peridex
Trial phase: Phase 2
SMILES: NC(=NCCCCCCN=C(N)N=C(N)Nc1ccc(Cl)cc1)N=C(N)Nc1ccc(Cl)cc1.O=C(O)C(O)C(O)C(O)C(O)CO.S
Sex: All
Age groups: Child
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 12
Group description: An oral rinse given to pediatric patients in routine practice within the standard of care.

Chlorhexidine gluconate (.12%): 30 second oral rinse expectorate of 10mL of solution
Eligibility criteria:
Inclusion Criteria:

Patients presenting to the dental clinic for routine dental treatment (including recall exams, new patient exams, and operative appointments) who are American Society of Anesthesia (ASA) class I or II
Cooperative patients classified as 3 or 4 according to the Frankl Behavioral Rating Scale,
No known allergies or sensitivities to products or ingredients being tested
Had untreated cavities
Nothing to eat/drink for 1 hour prior to dental appointment

Exclusion Criteria:

Patients who are ASA class III, IV, V or VI
Known allergies or sensitivities to any of the mouth rinses or any of the ingredients in the mouth rinses to be tested
Non-English speaking parent/participant
Patient presenting to the clinic as a walk in or emergency appointment
Patient experiencing any pain or sensitivity
Precooperative or uncooperative behavior or behavior classified as 1 or 2 according to the Frankl Behavioral Rating Scale